Nonetheless, we recommend reassessing the appropriateness of classifying as adverse risk AML patients with a single mutation in one of the so called MDS-related genes (ASXL1, BCOR, EZH2, RUNX1, SF3B1, SRSF2, STAG2, U2AF1, and ZRSR2) and no other adverse genetic factor [31]. Here, BCOR is linked to myelodysplastic syndrome.